| abstract |
The invention relates to new 9-substituted estratriennes of the general formula I, where R3, R7, R7 ', R13, R16 and R17 and R17' have the meanings indicated in the description, just as R9 is a linear chain alkenyl radical or branched, optionally partially or totally halogenated with 2 to 6 carbon atoms, an ethynyl or prop-1-inyl radical, as pharmaceutical active ingredients, which have a greater affinity in vitro in preparations of prostate estrogen receptor preparations of rat than in preparations of rat uterine estrogen receptors and which preferably have in vivo a preferential effect on the ovary compared to the uterus. The invention also relates to the preparation of these estratrienes, their therapeutic application and pharmaceutical administration forms containing the new compounds. The invention also relates to the use of these compounds for the treatment of diseases and conditions caused by estrogen deficiency. |